33 completed, 9 unknown, 8 recruiting, 6 terminated. 67 Phase 1, 32 Phase 2.
Follow Prednisolone: new trials by email Literature Review of Prednisolone trials Research Report on Prednisolone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis Steroid, Antibiotic - Granulomatous Mastitis | Phase 1 / Phase 2 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 72 | 2026-03-15 | 2026-03-06 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Vector Y Therapeutics | 36 | 2025-12-19 | 2026-10-30 |
| Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators ASP2957, Methylprednisolone, Prednisolone - X-Linked Myotubular Myopathy | Phase 1 / Phase 2 | Recruiting | Astellas Gene Therapies | 9 | 2025-12-15 | 2026-09-03 |
| A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL TRS005, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Teruisi Pharmaceutical Inc. | 66 | 2025-09-01 | 2025-08-22 |
| Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. Eltrombopag 25 MG, Prednisolone - Primary Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | Renata PLC | 100 | 2025-02-07 | 2025-02-18 |
| A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia ASP2016, Prednisolone - Friedreich Ataxia, Cardiomyopathy | Phase 1 | Withdrawn | Astellas Gene Therapies | 2024-11-08 | 2025-11-28 | |
| Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma Nivolumab - Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children | Phase 1 / Phase 2 | Enrolling by invitation | St. Petersburg State Pavlov Medical University | 22 | 2024-09-01 | 2025-03-11 |
| M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) M9466, Tuvusertib, Abiraterone acetate - Advanced Solid Tumor | Phase 1 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 60 | 2024-08-07 | 2026-09-09 |
| R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX) - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 108 | 2024-05-30 | 2026-06-10 |
| Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy Prednisolone, Cerebrolysin - Bell Palsy | Phase 1 / Phase 2 | Recruiting | October 6 University | 90 | 2023-08-24 | 2025-07-31 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone - Prostatic Neoplasms | Phase 1 | Terminated | Janssen Research & Development, LLC | 3 | 2022-03-23 | 2025-02-03 |
| Preparation and Characterization Intranasal Film Loaded With Steroid as a Local Treatment of Anosmia in Compare to Insulin Intranasal Film Prednisolone - Smell Loss | Phase 1 / Phase 2 | Completed | Deraya University | 200 | 2022-03-01 | 2023-06-01 |
| A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) Prednisolone, SPI-62 - Polymyalgia Rheumatica | Phase 1 | Terminated | Sparrow Pharmaceuticals | 1 | 2022-02-22 | 2025-05-16 |
| Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps. Montelukast, Prednisolone, Fluticasone Furoate - Montelukast, Chronic Rhinosinusitis With Nasal Polyps | Phase 1 / Phase 2 | Unknown | Assiut University | 60 | 2022-01-01 | 2022-03-18 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Obinutuzumab, Venetoclax, Magrolimab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2021-12-16 | 2025-02-04 |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma CC-220, Rituximab, Cyclophosphamide - Lymphoma, B-Cell | Phase 1 | Active not recruiting | Celgene | 224 | 2021-09-15 | 2026-07-20 |
Showing 20 of 67. Sign in to see all of them.
Lymphoma (6) · Prostatic Neoplasms (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, B-Cell (4) · Lymphoma, Follicular (4) · Pulmonary Disease, Chronic Obstructive (4) · Arthritis, Rheumatoid (2) · Asthma (2) · Immunoblastic Lymphadenopathy (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Ovarian Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
GlaxoSmithKline (7) · Novartis Pharmaceuticals (4) · Janssen Research & Development, LLC (3) · Astellas Gene Therapies (2) · AstraZeneca (2) · Celgene (2) · Children's Oncology Group (2) · Genentech, Inc. (2) · Lymphoma Trials Office (2) · Merck Sharp & Dohme LLC (2) · All India Institute of Medical Sciences, Bhubaneswar (1) · Armando Santoro, MD (1) · Asan Medical Center (1) · Assiut University (1) · Astex Pharmaceuticals, Inc. (1)
United States (24) · United Kingdom (16) · Australia (7) · Spain (7) · Canada (6) · France (6) · Germany (6) · Japan (6) · South Korea (6) · Belgium (4) · China (4) · Italy (4) · Netherlands (4) · Egypt (3) · Taiwan (3)
Ruth Pettengell, MD (2) · Andy Davies (1) · Armando Santoro, MD (1) · Brad Haverkos, MD (1) · Cheolwon Suh, M.D.,Ph.D. (1)
PMID 29550052, PMID 38258274, PMID 39319495, PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 19164344, PMID 19846889, PMID 19880675, PMID 20236866, PMID 23607606, PMID 24787968, PMID 24802773, PMID 25809824, PMID 29270980, PMID 29534336, PMID 29650362, PMID 30344993, PMID 30773077, PMID 30908082, PMID 31101489, PMID 32122924, PMID 32770353, PMID 33035457, PMID 34452956, PMID 35473729, PMID 37553297, PMID 37981564, PMID 39563886, PMID 39821757, PMID 40532125, PMID 40739200, PMID 42158929, PMID 42833056
2025 (4), 2019 (2), 2023 (2), 2008 (1), 2015 (1), 2016 (1), K12HD043494 (1), R01AI047040 (1), R01AI054843 (1), R42CA144104 (1), U10CA180886 (1)